{
  "id": "60292d191cb411341a00010e",
  "type": "factoid",
  "question": "What disease does BCG immunotherapy used to treat?",
  "ideal_answer": "Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy is used for treatment of bladder cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31755155",
    "http://www.ncbi.nlm.nih.gov/pubmed/23517232",
    "http://www.ncbi.nlm.nih.gov/pubmed/19957324",
    "http://www.ncbi.nlm.nih.gov/pubmed/12084297",
    "http://www.ncbi.nlm.nih.gov/pubmed/10575270",
    "http://www.ncbi.nlm.nih.gov/pubmed/26032289",
    "http://www.ncbi.nlm.nih.gov/pubmed/27241256",
    "http://www.ncbi.nlm.nih.gov/pubmed/15281319",
    "http://www.ncbi.nlm.nih.gov/pubmed/26000263",
    "http://www.ncbi.nlm.nih.gov/pubmed/31900581",
    "http://www.ncbi.nlm.nih.gov/pubmed/4412271",
    "http://www.ncbi.nlm.nih.gov/pubmed/6342739",
    "http://www.ncbi.nlm.nih.gov/pubmed/18976938",
    "http://www.ncbi.nlm.nih.gov/pubmed/28488840",
    "http://www.ncbi.nlm.nih.gov/pubmed/7016300",
    "http://www.ncbi.nlm.nih.gov/pubmed/31307960",
    "http://www.ncbi.nlm.nih.gov/pubmed/24064971",
    "http://www.ncbi.nlm.nih.gov/pubmed/29576423",
    "http://www.ncbi.nlm.nih.gov/pubmed/12057150",
    "http://www.ncbi.nlm.nih.gov/pubmed/178234",
    "http://www.ncbi.nlm.nih.gov/pubmed/30893148",
    "http://www.ncbi.nlm.nih.gov/pubmed/9259090",
    "http://www.ncbi.nlm.nih.gov/pubmed/27960233",
    "http://www.ncbi.nlm.nih.gov/pubmed/1244548",
    "http://www.ncbi.nlm.nih.gov/pubmed/8573479",
    "http://www.ncbi.nlm.nih.gov/pubmed/19967427",
    "http://www.ncbi.nlm.nih.gov/pubmed/28807024",
    "http://www.ncbi.nlm.nih.gov/pubmed/32577059",
    "http://www.ncbi.nlm.nih.gov/pubmed/25794874"
  ],
  "snippets": [
    {
      "text": "Bacillus Calmette-Gu\u00e9rin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31755155",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy for bladder cancer has been used since 1976 when the first evidence of its ability to lower recurrence and progression rates was published.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31755155",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BCG immunotherapy is the choice of care for high-grade non-muscle invasive bladder cancer (NMIBC) after transurethral resection.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31755155",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Renal Tuberculosis Following Intravesical Bacillus Calmette-Gu\u00e9rin (BCG) Immunotherapy for the Treatment of Bladder Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32577059",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Adjuvant BCG immunotherapy for stage I and II malignant melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/6342739",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Intravesical BCG (Bacillus Calmette-Guerin) immunotherapy has been widely used to treat NMIBC, but it fails to suppress recurrence of bladder tumors in up to 40% of patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26032289",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Presently, bacillus Calmette-Guerin (BCG) immunotherapy remains the most effective treatment and prophylaxis for TCC (Ta, Tl, CIS) and has positive outcomes on tumor recurrence rate, disease progression, and prolongation of survival.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9259090",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Response of high-risk of recurrence/progression bladder tumours expressing sialyl-Tn and sialyl-6-T to BCG immunotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24064971",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Data support that BCG has a positive impact on tumor recurrence, disease progression, and survival.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12084297",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "It is nearly 40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26000263",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Prostatic urethral mucosal involvement with bladder cancer can be effectively treated with BCG intravesical immunotherapy-it has demonstrated a reduction in tumor recurrence rates, but has had no positive impact on disease progression or prolongation of survival.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9259090",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25794874",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The advantage of BCG immunotherapy over intravesical chemotherapy in superficial bladder cancer has been most apparent in patients with carcinoma in situ (CIS), where complete response is increased from 50% to more than 70% and the proportion of patients remaining disease free for 5 years is increased from 20% to 40%. Similar",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15281319",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "dministration of Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy has become the standard of care for high-grade non-muscle invasive bladder cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention of recurrence and progression. While most a",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23517232",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES: Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy is regarded as the current treatment of choice for stage T1 grade 3 (T1G3) bladder cancer (BC), though its efficacy is limited by high recurrence and progression ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18976938",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Gu\u00e9rin (BCG), which activates the immune system to recognize and destroy malignant cells and has demonstrated durable clinical benefit. Urolo",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28807024",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Intravesical Mycobacterium bovis bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy is a highly effective treatment for carcinoma in situ of the bladder, as well as high-risk nonmuscle invasive urothelial carcinoma of the bladder. Desp",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19967427",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Intravesical immunotherapy with Mycobacterium bovis (M. bovis) bacillus Calmette-Guerin (BCG) is the current standard of care against superficial, high-grade transitional cell carcinoma (TCC) of the urinary bladder (carcinoma in situ and pathologic T1, grade 3 disease)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19957324",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "It is nearly 40 years since Bacillus Calmette-Gu\u00e9rin (BCG) was first used as an immunotherapy to treat superficial bladder cancer. Des",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26000263",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Intravesical immunotherapy with bacille Calmette-Gu\u00e9rin (BCG) vaccine is the main treatment for non-muscle-invasive bladder cancer (NMIBC), with proven effects on reducing recurrence, progression, and death from NMIBC. However",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31307960",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " propria invasive tumors and carcinoma in situ, intravesical immunotherapy with bacille Calmette-Gu\u00e9rin (BCG) is often the first line of treatment to decrease tumor recurrence and to possibly decrease progression and improve survival. Intravesical ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12057150",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although intravesical instillation of Bacille-Calmette-Guerin (BCG) immunotherapy was approved many decades ago as a first line therapy for intermediate to high-risk non-muscle invasive bladder cancer, its long-term efficacy is still arguable as a proportion of up to 30-40% of patients will develop recurrence or progression of their disease. Base",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27241256",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "FINDINGS: Although BCG has been used to treat high-risk NMIBC for decades, new applications of immunotherapy include the use of exogenous cytokines to boost immune response, vaccines to activate the immune system against specific tumor-associated antigens, intravesical agents that cause generalized local inflammation, and targeted antibodies against proteins on the surface of immune checkpoint inhibitors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30893148",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Drugs such as mitomycin C used after transurethral resection of bladder tumour to reduce recurrences, bacillus Calmette-Gu\u00e9rin (BCG) intravesical immunotherapy to treat high-risk non-muscle-invasive bladder cancer and urothelial CIS and platin-based systemic chemotherapy to improve postcystectomy disease-specific survival are examples of therapy-related atypia seen in the urinary tract.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27960233",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Mitomycin C used after transurethral resection of bladder tumor to reduce recurrences, BCG intravesical immunotherapy to treat high risk non-muscle invasive bladder cancer and urothelial carcinoma in situ, and platinum-based systemic chemotherapy to improve post-cystectomy disease-specific survival some of the causes of therapy related atypia in urinary bladder.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29576423",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This comprehensive review highlights recent developments in intravesical therapy of bladder cancer and summarizes the mechanisms of action of BCG, and the important role of intravesical BCG immunotherapy and other immunotherapeutic agents in the therapy and prophylaxis of superficial TCC of the urinary bladder.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/9259090",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The following two approaches to BCG immunotherapy were investigated at the Department of Urology of Padova University by specific Phase II and III trials designed to evaluate the possibility of reducing BCG-related side-effects without compromising therapeutic efficacy: (1) by reducing the dose of BCG per instillation 'low-dose' regimen, (2) by delaying the interval of the instillations 'slow-rate' regimen.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/10575270",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This review summarises the history and development of BCG as a modern cancer treatment, appraises current optimal application of BCG immunotherapy in bladder cancer, discusses promising new therapies closely related to BCG, and briefly explores the possibility that BCG or related treatments may have an application in other urological malignancies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23517232",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Immunotherapy by intravesicular delivery of Bacillus Calmette\u2013Gu\u00e9rin (BCG) is used to treat and prevent the recurrence of superficial bladder cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28488840",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy is currently the most effective treatment of non-muscle invasive bladder cancer and one of the most successful applications of immunotherapy to the treatment of cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23517232",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ": The administration of Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy has become the standard of care for high-grade non-muscle invasive bladder cancer (NMIBC) and carcinoma in-situ (CIS) in terms of prevention of recurrence and progression.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23517232",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The data establishing BCG immunotherapy as the standard of care for high-grade NMIBC and CIS over other bladder instillation modalities is presented in addition to the effect maintenance BCG therapy has on sustaining the immuno-protective effect.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23517232",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SUMMARY: When T1 high-grade non-muscle-invasive bladder cancer is persistent or recurs shortly after a full course of bacille Calmette-Gu\u00e9rin (BCG) plus maintenance, further BCG is not likely to work; this meets the new definition of a \"BCG unresponsive\" disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31307960",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31900581",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "-treatment PD-L1 expression was associated with unfavorable pathological features in primary high-grade NMIBC and its expression level after BCG immunotherapy was significantly decreased in patients with refractory recurrence. PD",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31900581",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "e reviewed a total of 141 high-grade NMIBC cases treated with transurethral resection\u2009+\u2009\u2009\u2265\u20096 BCG instillations between 2004 and 2017. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31900581",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Presently, BCG is commonly used and is the most effective immunotherapeutic agent against superficial transitional cell carcinoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/12084297",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In the past three decades, intravesical instillation of Mycobacterium bovis bacille Calmette-Gu\u00e9rin (BCG) has been used for treating bladder cancer and it still remains at the forefront of immunotherapy for cancer patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25794874",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Although BCG-based therapy is the most effective intravesical therapy for this kind of tumor and represents the only agent known to reduce progression into muscle invasive bladder cancer, BCG is ineffective in approximately 30-40 % of cases and disease recurs in up to 50 % of patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25794874",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Since that BCG is considered an effective vehicle for delivery of antigens due to its unique characteristics, the genetic manipulation of these mycobacteria has been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer immunotherapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25794874",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Adjuvant immunotherapy with BCG in treatment of regional-lymph-node metastases from malignant melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/1244548",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BCG immunotherapy for transitional-cell carcinoma in situ of the bladder.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8573479",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BCG immunotherapy of bladder cancer: inhibition of tumor recurrence and associated immune responses.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/7016300",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Early experiences with BCG immunotherapy for malignant melanoma and C. parvum for oat cell carcinoma are encouraging.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/178234",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Bacillus Calmette-Gu\u00e9rin immunotherapy for genitourinary cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23517232",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Over the past 7 years, 151 patients with malignant melanoma have been treated with BCG immunotherapy alone or as an adjunct to surgical therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/4412271",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "bladder cancer, bladder cancer (NMIBC), high-grade non-muscle invasive bladder cancer (NMIBC)"
}